Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis

Archives of Ophthalmology

Volumn 123, Issue 5, 2005, Pages 654-661

  Li, Haochuan ^a   Niederkorn, Jerry Y ^a   Neelam, Sudha ^a   Alizadeh, Hassan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 8; DACTINOMYCIN; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BIRC5 PROTEIN, HUMAN; CASP10 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASPASE; LIGAND; MEMBRANE PROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA MELANOMA; WESTERN BLOTTING; APOPTOSIS; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; UVEA TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASE 10; CASPASE 8; CASPASES; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; LIGANDS; MELANOMA; MEMBRANE GLYCOPROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; UVEAL NEOPLASMS;

EID: 18444361800     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.5.654     Document Type: Article

References (44)

1. Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer. 1987;40:161-164.
2. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239-251.
3. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark. 1943-1952. Acta Ophthalmol (Copenh). 1982;60:161-182.
4. Shammas HF, Blodi FC. Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol. 1977;95:63-69.
5. Zimmerman LE, McLean IW. An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol. 1979;87:741-760.
6. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer. 1993;71:2299-2305.
7. van der Pol JP, Blom DJ, Flens MJ, et al. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines. Invest Ophthalmol Vis Sci. 1997;38:2523-2530.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-12690.
9. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111-113.
10. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997;16:5386-5397.
11. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 1997;7:1003-1006.
12. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.
13. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815-818.
14. Ren DH, Mayhew E, Hay C, Li H, Alizadeh H, Niederkorn JY. Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci. 2004;45:1162-1168.
15. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2000;2:241-243.
16. Eggert A, Grotzer MA, Zuzak TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001;61:1314-1319.
17. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865-5877.
18. Griffith TS, Fialkov JM, Scott DL, et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 2002;62:3093-3099.
19. Grossman D, Kim PJ, Blanc-Brude OP, et al.Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest. 2001;108:991-999.
20. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981-990.
21. Reed JC. The Survivin saga goes in vivo. J Clin Invest. 2001;108:965-969.
22. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076-1081.
23. Matsuzaki H, Schmied BM, Ulrich A, et al. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001;7:407-414.
24. Huang XQ, Mitchell MS, Liggett PE, Murphree AL, Kan-Mitchell J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol Immunother. 1994;38:399-405.
25. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997;73:470-478.
26. De Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995;62:155-161.
27. Albert DM, Ruzzo MA, McLaughlin MA, Robinson NL, Craft JL, Epstein J. Establishment of cell lines of uveal melanoma: methodology and characteristics. Invest Ophthalmol Vis Sci. 1984;25:1284-1299.
28. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000;165:710-715.
29. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6:529-535.
30. Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62:5897-5901.
31. Belloc F, Belaud-Rotureau MA, Lavignolle V, et al. Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry. 2000;40:151-160.
32. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003;63:230-235.
33. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
34. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998;161:2833-2840.
35. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001;98:635-640.
36. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
37. LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002;8:274-281.
38. Degli-Esposti M. To die or not to die: the quest of the TRAIL receptors. J Leukoc Biol. 1999;65:535-542.
39. Petak I, Vernes R, Szucs KS, et al. A caspase-8-independent component in TRAIL/ Apo-2L-induced cell death in human rhabdomyosarcoma cells. Cell Death Differ. 2003;10:729-739.
40. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene. 2001;20:2122-2133.
41. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
42. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev. 1999;13:239-252.
43. Hawkins CJ, Vaux DL. The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Semin Immunol. 1997;9:25-33.
44. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol. 1998;10:552-558.